J&J Venture Arm Invests in Delix Therapeutics’ $100 Million Series C

Johnson & Johnson Innovation’s venture arm, JJDC, and SV Health Investors’ Dementia Discovery Fund led Delix Therapeutics’ $100 million Series C. Delix is developing psychedelic-compound versions without hallucinatory effects.